StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Research by Quarter

Research — Collaborative & upfront licensing payments (FY2015–FY2021, $M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals Research: $51.2M in Q4 2021, up 24.0% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2021
51.2
Period ended Dec 31, 2021
Change on a year earlier
+24.0%
41.3 in Q4 2020
History
17 quarters
Since Q3 2017
Sources
12
Documents cited below

Where the Q4 2021 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗

Reported in Form 10-Q / 10-K MD&A (reclassified to separate AIPR&D line from FY2022).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedResearch — Collaborative & upfront licensing payments (FY2015–FY2021, $M) ($M)Year on yearSource
Q4 2021Dec 31, 202151.2+24.0%Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗
Q3 2021Sep 30, 202126.8-66.5%Form 10-Q (vrtx-20210930.htm, filed 2021-11-03) ↗
Q2 2021Jun 30, 202125.8-4.4%Form 10-Q (vrtx-20210630.htm, filed 2021-07-30) ↗
Q1 2021Mar 31, 20211.60-95.6%Form 10-Q (vrtx-20210331.htm, filed 2021-04-30) ↗
Q4 2020Dec 31, 202041.3-27.0%Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗
Q3 2020Sep 30, 202080-59.8%Form 10-Q (vrtx-20210930.htm, filed 2021-11-03) ↗
Q2 2020Jun 30, 202027-48.3%Form 10-Q (vrtx-20210630.htm, filed 2021-07-30) ↗
Q1 2020Mar 31, 202036.2–Form 10-Q (vrtx-20210331.htm, filed 2021-04-30) ↗
Q4 2019Dec 31, 201956.6-47.2%Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗
Q3 2019Sep 30, 2019199+10,955.6%Form 10-Q (vrtx-20200930.htm, filed 2020-10-30) ↗
Q2 2019Jun 30, 201952.2+2,169.6%Form 10-Q (vrtx-20200630.htm, filed 2020-07-31) ↗
Q4 2018Dec 31, 2018107+1,240.0%Form 10-K (vrtx-20201231.htm, filed 2021-02-11) ↗
Q3 2018Sep 30, 20181.80+350.0%Form 10-Q (a2019q310-q.htm, filed 2019-10-31) ↗
Q2 2018Jun 30, 20182.30–Form 10-Q (a2019q210-q.htm, filed 2019-08-01) ↗
Q1 2018Mar 31, 20180.30–Form 10-Q (a2019q110-q.htm, filed 2019-05-01) ↗
Q4 2017Dec 31, 20178–Form 10-K (a201910k-main.htm, filed 2020-02-13) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Research ($M), quarterly Q3 2017–Q4 2021 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-res-collab

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.